|Optimizing Treatment in Low-risk MDS: Current and Future Standard of Care in Patients with Non-deletion 5q|
Olatoyosi Odenike, MD
|Release Date: June 25, 2018|
Expiration Date: June 25, 2019
Appropriately managing low-risk MDS patients with non-del(5q) requires a strong understanding of treatment goals and practice challenges. This activity will outline appropriate treatment strategies for low-risk MDS with non-del(5q) and will evaluate how recent advances and emerging options may change the current standard of care in this patient population.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Onconova Therapeutics Inc.
|Begin, Earn CreditView Only, No Credit|